Medifast

Medifast reported a narrower Q2 loss of $0.28 per share and revenue of $76.4 million, both slightly better than analysts had expected. Despite a 27.6% decline in revenue and a steep drop in active coaches, productivity per coach rose significantly. The launch of the Trilivy brand and cost-cutting measures are intended to support a repositioning toward metabolic health and put the company on track to return to profitability in Q4 2026. The stock gained about 14% after-hours while Medifast left its full-year guidance unchanged. » Mere på de.investing.com

Medifast is introducing the Trilivy system to replace the OPTAVIA brand and is offering reformulated meal-replacement products called Trilivy Reset Fueling that use MetaVantage technology. The rebranding signals a strategic shift from pure weight loss toward addressing metabolic health with a three-phase program (Reset, Refine, Renew) and a network of independent coaches. The company notes a 36% decline in revenue but a 70% gross profit margin; the new products are slated to launch in August and are intended to positively impact visceral fat as well as insulin and fat metabolism. » Mere på de.investing.com

Medifast’s board has appointed Nicholas Johnson as chief executive officer effective June 1, 2026; Dan Chard remains chairman of the board. The appointment follows a succession plan announced in January; Johnson most recently served as president and has held various leadership roles since 2018. Medifast faces strong headwinds: revenue fell 36% over the past twelve months to $346.1 million and the company posted a loss of $1.82 per share, with analysts not expecting a return to profitability this year. Despite the troubles, gross profit margin remains high at 70%, the stock is up 17.9% year-to-date and trades around $13.08 with a market capitalization of about $132.6 million. » Mere på de.investing.com

Medifast reported Q1 2026 EPS of -$0.19, beating the estimate of -$0.36, while revenue of $76 million missed expectations of $85.5 million. The stock fell about 2.6% premarket and is approaching its 52-week low. The company recorded its first sequential revenue growth in three years and improved coach productivity, but still expects declining revenues and forecasted further EPS losses. Management is focusing on operational efficiency and a metabolic system planned for July 2026, but sees risks from GLP-1 drugs and continued revenue declines. » Mere på de.investing.com

Medifast reported a loss per share of $1.65 for Q4 2025 on revenue of $75 million, with revenue slightly above expectations but profitability dropping sharply. Gross margin fell by 470 basis points, active coaches declined while revenue per active coach rose 6%. For 2026 the company forecasts revenue of $270–300 million and continued losses, but expects a profit recovery from Q4 2026 driven by new products, operational savings of over $30 million, a strong liquidity position of $167 million and debt-free status. » Mere på de.investing.com